US jury slaps $9 bn fine on drugmakers

Image
IANS
Last Updated : Apr 09 2014 | 6:17 AM IST

Washington, April 9 (IANS/EFE) A US federal court jury imposed fines and compensations for a value of some $9 billion on drug manufacturers -- Takeda Pharmaceutical Co. and Eli Lilly & Co. -- for their cover-up of the cancer risks found in their diabetes medication Actos.

The jury in Lafayette, Louisiana, ordered Japan's Takeda to pay $6 billion, while its partner Lilly, based in Indianapolis, Indiana, was handed a penalty of $3 billion.

"I hope Takeda executives in Japan heard what this jury had to say loudly and clearly," Mark Lanier, a lawyer representing former Actos user Terrence Allen, said.

The jury had already awarded $1.5 billion in compensatory damages to Allen, who blamed the medication for developing his cancer of the bladder.

The judgment is one of the largest in the history of the US, but will probably be reduced because the Supreme Court has ruled that punitive damages should be proportional to compensatory damages.

In the previous 10 cases with the largest punitive damages, no company has paid the amounts requested by this jury.

Takeda, the biggest drugmaker in Japan and one of the 15 largest in the world, expressed in a communique its disagreement with the ruling. The company said it would appeal the sentence, while Lilly, its partner, issued a similar statement separately.

--IANS/EFE

sd

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 09 2014 | 6:12 AM IST

Next Story